Cart
sales@molnova.com
GSK8573
CAS No. 1693766-04-9
GSK8573( —— )
Catalog No. M22027 CAS No. 1693766-04-9
GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 50 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 132 | In Stock |
|
| 25MG | 248 | In Stock |
|
| 50MG | 370 | In Stock |
|
| 100MG | 537 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK8573
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
-
DescriptionGSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
-
In VitroGSK8573 (1.0 μM) has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain family.
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorBRD9
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1693766-04-9
-
Formula Weight323.39
-
Molecular FormulaC20H21NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO:22 mg/mL (68.03 mM; Need ultrasonic)
-
SMILESCCCOC1=CC2=C(C=C(N2C=C1)C(C)=O)C1=CC(OC)=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chen P, et al. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. J Med Chem. 2016 Feb 25;59(4):1410-24.
molnova catalog
related products
-
IRAK4-IN-1
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
-
SRX3177
SRX3177 is a novel and potent inhibitor of BRD4, PI3K and CDK.SRX3177 has potential anticancer activity.
-
BAZ1A-IN-1
BAZ1A-IN-1 is a potent BAZ1A inhibitor with the KD value of 0.52 μM for the BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-survival activity against cancer cell lines with high BAZ1A expression, but weak or no activity against cancer cells with low BAZ1A expression.
